Evaluating Calcitonin Gene-Related Peptide Inhibitors: A Superior Option for Migraine Prevention?

Migraine affects 6% to 8% of the population and is the leading cause of disability in women younger than 50 years old. Traditional treatments often rely on trial and error, whereas recent advancements offer a promising alternative: calcitonin gene-related peptide (CGRP) inhibitors. They have consistently demonstrated significant reductions in monthly migraine days with few adverse effects, leading to improved patient adherence. However, high costs and limitations of CGRP for use in pregnancy and in those with recent ischemic events remain a barrier to access. Overall, CGRP inhibitors demonstrate superior efficacy and safety, with rapid action onset for preventive and episodic migraine treatment.